Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study on the Hepatic Uptake, Pharmacokinetics, Safety and Tolerance of a New Oral Pentamidine Formulation in Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation

NCT02210182 is registered in ClinicalTrials.gov with Oncozyme Pharma Inc. as lead sponsor.

NCT NCT02210182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02210182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study on the Hepatic Uptake, Pharmacokinetics, Safety and Tolerance of a New Oral Pentamidine Formulation in Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation
Lead sponsor
Oncozyme Pharma Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2014
Completion date
December 31, 2015
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma